We are live on ! Find out more
MIM

Monashee Investment Management Portfolio holdings

AUM $184M
1-Year Est. Return 197.43%
This Fund
S&P 500
This Quarter Est. Return
+12.36%
1 Year Est. Return
+197.43%
3 Year Est. Return
+447.04%
5 Year Est. Return
+479.31%
10 Year Est. Return
+5,610.42%
AUM
$525M
AUM Growth
+$163M
Cap. Flow
-$365M
Cap. Flow %
-69.47%
Top 10 Hldgs %
34.54%
Holding
251
New
–
Increased
–
Reduced
–
Closed
140

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$17.3M
2
GIS icon
General Mills
GIS
+$16.1M
3
HGV icon
Hilton Grand Vacations
HGV
+$13.9M
4
D icon
Dominion Energy
D
+$13.5M
5
ACGL icon
Arch Capital
ACGL
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 20.2%
2 Financials 16.74%
3 Technology 15.78%
4 Industrials 10.99%
5 Energy 7.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
26
DELISTED
Sage Therapeutics
SAGE
– –
-110,000
Closed -$17.3M
BABA icon
27
Alibaba
BABA
$304B
– –
0
– –
GSAH.U
28
DELISTED
GS Acquisition Holdings Corp. Units, each consisting of one share of Class A common stock and one-th
GSAH.U
– –
0
– –
AVLR
29
DELISTED
Avalara, Inc.
AVLR
– –
0
– –
USAC icon
30
USA Compression Partners
USAC
$3.78B
– –
0
– –
DEA
31
Easterly Government Properties
DEA
$1.18B
– –
0
– –
GRBK icon
32
Green Brick Partners
GRBK
$3.07B
– –
0
– –
GFF icon
33
Griffon
GFF
$4.81B
– –
0
– –
TSG
34
DELISTED
The Stars Group Inc.
TSG
– –
0
– –
AZUL
35
DELISTED
Azul
AZUL
– –
-27,000
Closed -$678K
I
36
DELISTED
INTELSAT S. A.
I
– –
0
– –
FPAC.U
37
DELISTED
Far Point Acquisition Corporation Units, each consisting of one share of Class A common stock, $0.00
FPAC.U
– –
0
– –
CHRA
38
DELISTED
Charah Solutions, Inc Common Stock
CHRA
– –
0
– –
APTX
39
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
0
– –
ALTR
40
DELISTED
Altair Engineering Inc
ALTR
– –
0
– –
USX
41
DELISTED
U.S. Xpress Enterprises, Inc. Class A Common Stock
USX
– –
0
– –
COOP
42
DELISTED
Mr. Cooper
COOP
– –
-58,333
Closed -$963K
RYTM icon
43
Rhythm Pharmaceuticals
RYTM
$7.72B
– –
0
– –
AUTL
44
Autolus Therapeutics
AUTL
$532M
– –
0
– –
CRZO
45
DELISTED
Carrizo Oil & Gas Inc
CRZO
– –
0
– –
MRTX
46
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
0
– –
DOMO icon
47
Domo
DOMO
$179M
– –
0
– –
ETR icon
48
Entergy
ETR
$49.7B
– –
0
– –
KURA icon
49
Kura Oncology
KURA
$824M
– –
0
– –
WMS icon
50
Advanced Drainage Systems
WMS
$11.4B
– –
0
– –
1
2
3 4 5

Similar funds

SWMG
Sard Wealth Management Group Atlanta, Georgia $184M AUM 11.26% 1-Year Est. Return
IFPL
Investments & Financial Planning LLC Lexington, Kentucky $184M AUM 17.7% 1-Year Est. Return
RFG
RFP Financial Group Atlanta, Georgia $184M AUM 16.06% 1-Year Est. Return
NAM
Nutshell Asset Management Sevenoaks, United Kingdom $184M AUM 2.02% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return
TCM
Tassel Capital Management Matthews, North Carolina $184M AUM 17.12% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
GCA
GSI Capital Advisors Newport Beach, California $184M AUM 5.17% 1-Year Est. Return

Monashee Investment Management's Q2 2018 Portfolio in Review

As of Q2 2018, Monashee Investment Management held 251 positions worth $525M, up 45% from $362M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Monashee Investment Management withdrew a net $365M in Q2 2018, closing 140 positions. Its most notable exit was Sage Therapeutics, an estimated $17.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Financials and Technology.

  • Monashee Investment Management fully exited Sage Therapeutics in Q2 2018, selling an estimated $17.3M.
  • Monashee Investment Management's ten largest holdings make up 35% of its $525M portfolio in Q2 2018.
  • Monashee Investment Management opened 0 new positions and closed 140 in Q2 2018.
  • Monashee Investment Management's portfolio value rose 45% quarter-over-quarter to $525M.

Based on Monashee Investment Management's 13F filing for Q2 2018, filed 10 Aug 2018.